01 7Opalmon
02 4Prorenal
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 56
2019 Revenue in Millions : 84
Growth (%) : -33
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 41
2020 Revenue in Millions : 54
Growth (%) : -19
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 34
2021 Revenue in Millions : 41
Growth (%) : -16
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 26
2022 Revenue in Millions : 34
Growth (%) : -14
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2016 Revenue in Millions : 63
2015 Revenue in Millions : 84
Growth (%) : -25
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2017 Revenue in Millions : 57
2016 Revenue in Millions : 67
Growth (%) : -16
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2018 Revenue in Millions : 38
2017 Revenue in Millions : 49
Growth (%) : -22%
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 32
2018 Revenue in Millions : 39
Growth (%) : -19
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2017 Revenue in Millions : 146
2016 Revenue in Millions : 173
Growth (%) : -16
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2018 Revenue in Millions : 120
2017 Revenue in Millions : 137
Growth (%) : -13%
LOOKING FOR A SUPPLIER?
